U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C33H40N2O9
Molecular Weight 608.6787
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of RESERPINE

SMILES

[H][C@]12C[C@@H](OC(=O)C3=CC(OC)=C(OC)C(OC)=C3)[C@H](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@@]4([H])N(CCC5=C4NC6=C5C=CC(OC)=C6)C2

InChI

InChIKey=QEVHRUUCFGRFIF-MDEJGZGSSA-N
InChI=1S/C33H40N2O9/c1-38-19-7-8-20-21-9-10-35-16-18-13-27(44-32(36)17-11-25(39-2)30(41-4)26(12-17)40-3)31(42-5)28(33(37)43-6)22(18)15-24(35)29(21)34-23(20)14-19/h7-8,11-12,14,18,22,24,27-28,31,34H,9-10,13,15-16H2,1-6H3/t18-,22+,24-,27-,28+,31+/m1/s1

HIDE SMILES / InChI
Reserpine is an alkaloid, isolated from the Rauwolfia serpentina plant and developed by Ciba pharma. Reserpine was approved by FDA for the treatment of hypertension and psychotic disorders. The drug exerts its effect by blocking two vesicular monoamine transporters, VMAT1 and VMAT2. The blockade results in vesicles that lose their ability to store neurotransmitter molecules. Neurotransmitters, thus retained in cytosol, are then neutralized by MAO.

Originator

Curator's Comment: Later Ciba-Geigy and now Novartis.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
160.0 nM [IC50]
350.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
RESERPINE

Approved Use

Mild essential hypertension; also useful as adjunctive therapy with other antihypertensive agents in the more severe forms of hypertension; relief of symptoms in agitated psychotic states (e.g., schizophrenia), primarily in those individuals unable to tolerate phenothiazine derivatives or in those who also require antihypertensive medication.

Launch Date

-4.66300797E11
Palliative
RESERPINE

Approved Use

Mild essential hypertension; also useful as adjunctive therapy with other antihypertensive agents in the more severe forms of hypertension; relief of symptoms in agitated psychotic states (e.g., schizophrenia), primarily in those individuals unable to tolerate phenothiazine derivatives or in those who also require antihypertensive medication.

Launch Date

-4.66300797E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
0.2 ng/mL
2.5 mg single, oral
dose: 2.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RESERPINE plasma
Equus caballus
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
4.8 ng × h/mL
2.5 mg single, oral
dose: 2.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RESERPINE plasma
Equus caballus
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
23.6 h
2.5 mg single, oral
dose: 2.5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
RESERPINE plasma
Equus caballus
population: HEALTHY
age: ADULT
sex: MALE
food status: FED
Doses

Doses

DosePopulationAdverse events​
0.25 mg 2 times / day multiple, oral
Dose: 0.25 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.25 mg, 2 times / day
Sources:
unhealthy, 41.2 years
n = 60
Health Status: unhealthy
Condition: cocaine dependence
Age Group: 41.2 years
Sex: M+F
Population Size: 60
Sources:
Disc. AE: Drowsiness, Light headedness...
AEs leading to
discontinuation/dose reduction:
Drowsiness (1 patient)
Light headedness (light, 1 patient)
Sources:
0.25 mg 2 times / day multiple, oral
Dose: 0.25 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.25 mg, 2 times / day
Sources:
unhealthy, 41.2 years
n = 60
Health Status: unhealthy
Condition: cocaine dependence
Age Group: 41.2 years
Sex: M+F
Population Size: 60
Sources:
Disc. AE: Upper abdominal pain, Postural hypotension...
AEs leading to
discontinuation/dose reduction:
Upper abdominal pain (1 patient)
Postural hypotension (1 patient)
Electrocardiogram abnormal (1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Drowsiness 1 patient
Disc. AE
0.25 mg 2 times / day multiple, oral
Dose: 0.25 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.25 mg, 2 times / day
Sources:
unhealthy, 41.2 years
n = 60
Health Status: unhealthy
Condition: cocaine dependence
Age Group: 41.2 years
Sex: M+F
Population Size: 60
Sources:
Light headedness light, 1 patient
Disc. AE
0.25 mg 2 times / day multiple, oral
Dose: 0.25 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.25 mg, 2 times / day
Sources:
unhealthy, 41.2 years
n = 60
Health Status: unhealthy
Condition: cocaine dependence
Age Group: 41.2 years
Sex: M+F
Population Size: 60
Sources:
Electrocardiogram abnormal 1 patient
Disc. AE
0.25 mg 2 times / day multiple, oral
Dose: 0.25 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.25 mg, 2 times / day
Sources:
unhealthy, 41.2 years
n = 60
Health Status: unhealthy
Condition: cocaine dependence
Age Group: 41.2 years
Sex: M+F
Population Size: 60
Sources:
Postural hypotension 1 patient
Disc. AE
0.25 mg 2 times / day multiple, oral
Dose: 0.25 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.25 mg, 2 times / day
Sources:
unhealthy, 41.2 years
n = 60
Health Status: unhealthy
Condition: cocaine dependence
Age Group: 41.2 years
Sex: M+F
Population Size: 60
Sources:
Upper abdominal pain 1 patient
Disc. AE
0.25 mg 2 times / day multiple, oral
Dose: 0.25 mg, 2 times / day
Route: oral
Route: multiple
Dose: 0.25 mg, 2 times / day
Sources:
unhealthy, 41.2 years
n = 60
Health Status: unhealthy
Condition: cocaine dependence
Age Group: 41.2 years
Sex: M+F
Population Size: 60
Sources:
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no [Activation >3.9811 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no
no
unlikely [Inhibition 20 uM]
weak [IC50 133 uM]
weak [IC50 133 uM]
weak [IC50 58 uM]
yes [IC50 2.8 uM]
yes [IC50 20.4 uM]
yes [IC50 26.3 uM]
yes [IC50 <0.03 uM]
yes [IC50 <0.2 uM]
yes [Inhibition 20 uM]
yes [Inhibition 20 uM]
yes [Ki 1.38 uM]
yes [Ki 295 uM]
yes
yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Pharmacological analysis of a new anorexic substance: 5-hydroxy-5(4'-chlorophenyl)-2, 3-dihydro-5H-imidazo-(2, 1-a) isoindole (Mazindol).
1975 Apr
Antagonistic effect of cyproheptadine on neuroleptic-induced catalepsy.
1975 Jan-Feb
[Behavior pharmacology of maprotiline, a new antidepressant].
1975 Nov
Transient global amnesia associated with cardiac arrhythmia and digitalis intoxication.
1975 Sep-Oct
On the anticataleptic action of cyproheptadine.
1976 Aug
Antidepressant effect of an ethanolic extract of the leaves of Cissampelos sympodialis in rats and mice.
1998 Dec
Reserpine modulates serotonin transporter mRNA levels in the rat brain.
1999
The adrenergic receptor agonist, clonidine, potentiates the anti-parkinsonian action of the selective kappa-opioid receptor agonist, enadoline, in the monoamine-depleted rat.
1999 Dec
The role of the sympathetic nervous system in the regulation of leptin synthesis in C57BL/6 mice.
1999 Feb 12
Modulation of gastrin processing by vesicular monoamine transporter type 1 (VMAT1) in rat gastrin cells.
1999 Jun 1
The group II metabotropic glutamate receptor agonist, DCG-IV, alleviates akinesia following intranigral or intraventricular administration in the reserpine-treated rat.
2000 Feb
Brain alpha(2)-adrenoceptors in monoamine-depleted rats: increased receptor density, G coupling proteins, receptor turnover and receptor mRNA.
2001 Apr
Blood pressure-independent effect of angiotensin AT1 receptor blockade on renal endothelin-1 production in hypertensive uremic rats.
2001 Aug
A sensitive method for the determination of gemfibrozil in human plasma samples by RP-LC.
2001 Aug
Simultaneous determination of olanzapine, clozapine and demethylated metabolites in serum by on-line column-switching high-performance liquid chromatography.
2001 Aug 5
The role of the D(2) dopamine receptor (D(2)R) in A(2A) adenosine receptor (A(2A)R)-mediated behavioral and cellular responses as revealed by A(2A) and D(2) receptor knockout mice.
2001 Feb 13
Determination of vitamin B(6) in cooked sausages.
2001 Jan
Separation of the insecticidal pyrethrin esters by capillary electrochromatography.
2001 Jan 5
Liquid chromatographic method with electrochemical detection for determination of cisapride in serum.
2001 Jan-Feb
Determination of famotidine in low-volume human plasma by normal-phase liquid chromatography/tandem mass spectrometry.
2001 Jul
Analysis of phenolic constituents of biological interest in red wines by high-performance liquid chromatography.
2001 Jul 13
Direct analysis of urinary trans,trans-muconic acid by coupled column liquid chromatography and spectrophotometric ultraviolet detection: method applicability to human urine.
2001 Jul 15
Application of conventional UV, photodiode array (PDA) and fluorescence (FL) detection to analysis of phenolic acids in plant material and pharmaceutical preparations.
2001 Mar
Quantitation of itraconazole in rat heparinized plasma by liquid chromatography-mass spectrometry.
2001 Mar 5
Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats.
2001 May
Determination of 3'-azido-2',3'-dideoxyuridine in maternal plasma, amniotic fluid, fetal and placental tissues by high-performance liquid chromatography.
2001 May 5
Determination of aliphatic amines in water by liquid chromatography using solid-phase extraction cartridges for preconcentration and derivatization.
2001 Oct
Rapid high-performance liquid chromatographic method for the separation of hydroxylated testosterone metabolites.
2001 Sep 5
Behavioral effects of MK-801 on reserpine-treated mice.
2002 Apr
Temperature effect on peak width and column efficiency in subcritical water chromatography.
2002 Feb
Direct-injection HPLC assay for the determination of a new carbapenem antibiotic in human plasma and urine.
2002 Feb 1
Simultaneous determination of cloricromene and its active metabolite in rabbit aqueous humor by high-performance liquid chromatography.
2002 Feb 5
Nitecapone and selegiline as effective adjuncts to L-DOPA in reserpine-induced catatonia in mice.
2002 Jan-Feb
Determination of L-sesamin and L-asarinin in Zanthoxylum(Roxb.) DC. by high performance liquid chromatography.
2002 Jul
Determination of terbutaline sulfate and its degradation products in pharmaceutical formulations using LC.
2002 Jul 31
Development and optimization of a reversed-phase high-performance liquid chromatographic method for the determination of piperacillin and tazobactam in tazocin injectable powder.
2002 Jul 31
[The effect of shourong compound formula on levels of dopamine and its metabolites in brain of Parkinson's disease mice induced by reserpine].
2002 May
LC-MS/MS determination of a farnesyl transferase inhibitor in human plasma and urine.
2002 Nov 7
Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.
2002 Oct
Development and substantiation of a liquid chromatographic method for monitoring organic reactions involved in synthesis of 4-methoxyphenylacetic acid.
2002 Oct 4
The physiology of overwintering in a turtle that occupies multiple habitats, the common snapping turtle (Chelydra serpentina).
2002 Sep-Oct
Determination of peptides and amino acids from wool and beer with sensitive fluorescent reagent 2-(9-carbazole)-ethyl chloroformate by reverse phase high-performance liquid chromotography and liquid chromotography mass spectrometry.
2003 Feb 1
Antitumour 2-(4-aminophenyl)benzothiazoles generate DNA adducts in sensitive tumour cells in vitro and in vivo.
2003 Feb 10
Growth-inhibitory effects of the chemopreventive agent indole-3-carbinol are increased in combination with the polyamine putrescine in the SW480 colon tumour cell line.
2003 Jan 14
Analysis of flecainide and two metabolites in biological specimens by HPLC: application to a fatal intoxication.
2003 Jan-Feb
Quercetin potentiates L-Dopa reversal of drug-induced catalepsy in rats: possible COMT/MAO inhibition.
2003 Jun
Patents

Sample Use Guides

Hypertension: In the average patient not receiving other antihypertensive agents, the usual initial dosage is 0.5 mg daily for 1 or 2 weeks. For maintenance, reduce to 0.1-0.25 mg daily. Psychiatric Disorders: the usual initial dosage is 0.5 mg daily, but may range from 0.1 mg to 1.0 mg. Adjust dosage upward or downward according to the patient's response.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Name Type Language
RESERPINE
EP   HSDB   INN   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
INN  
Official Name English
RESERPINE COMPONENT OF CAM-AP-ES
Common Name English
HYDRALAZINE HYDROCHLORIDE-HYDROCHLOROTHIAZIDE-RESERPINE COMPONENT RESERPINE
Common Name English
YOHIMBAN-16-CARBOXYLIC ACID, 11,17-DIMETHOXY-18-((3,4,5-TRIMETHOXYBENZOYL)OXY)-, METHYL ESTER, (3.BETA.,16.BETA.,17.ALPHA.,18.BETA.,20.ALPHA.)-
Common Name English
SERPASIL
Brand Name English
HYDRAP-ES COMPONENT RESERPINE
Common Name English
RESERPINE COMPONENT OF SER-A-GEN
Common Name English
RESERPINE [WHO-IP]
Common Name English
METATENSIN COMPONENT RESERPINE
Common Name English
RESERPINE [JAN]
Common Name English
ENT-50146
Code English
RESERPINE COMPONENT OF HYDROMOX R
Common Name English
SANDRIL
Brand Name English
RESERPINE [MI]
Common Name English
REGROTON COMPONENT RESERPINE
Common Name English
CAM-AP-ES COMPONENT RESERPINE
Common Name English
RESERPINE [USP MONOGRAPH]
Common Name English
DIUTENSEN-R COMPONENT RESERPINE
Common Name English
RESERPINE [ORANGE BOOK]
Common Name English
SER-A-GEN COMPONENT RESERPINE
Common Name English
RESERPINE COMPONENT OF HYDRALAZINE HYDROCHLORIDE-HYDROCHLOROTHIAZIDE-RESERPINE
Common Name English
RESERPINE [EP MONOGRAPH]
Common Name English
RESERPINE COMPONENT OF SALUTENSIN
Common Name English
RESERPINE [MART.]
Common Name English
RESERPINE COMPONENT OF DIUTENSEN-R
Common Name English
HYDROSERPINE PLUS (R-H-H) COMPONENT RESERPINE
Common Name English
RAU-SED
Brand Name English
RESERPINE [HSDB]
Common Name English
NSC-237659
Code English
RESERPINE COMPONENT OF DRALSERP
Common Name English
RESERPINE COMPONENT OF METATENSIN
Common Name English
RESERPINE COMPONENT OF HYDROPRES
Common Name English
RESERPINUM [WHO-IP LATIN]
Common Name English
RENESE-R COMPONENT RESERPINE
Common Name English
RESERPINE COMPONENT OF SERPASIL-ESIDRIX
Common Name English
RESERPINUM
HPUS   WHO-IP LATIN  
Common Name English
RESERPINE COMPONENT OF RENESE-R
Common Name English
H.R.-50 COMPONENT RESERPINE
Common Name English
RESERPINE COMPONENT OF HYDRO-RESERP
Common Name English
RESERPINE COMPONENT OF REGROTON
Common Name English
RESERPINE COMPONENT OF HYDRAP-ES
Common Name English
RESERPINE [VANDF]
Common Name English
RESERPINE COMPONENT OF DEMI-REGROTON
Common Name English
RESERPINE COMPONENT OF SERPASIL-APRESOLINE
Common Name English
HYDROMOX R COMPONENT RESERPINE
Common Name English
DEMI-REGROTON COMPONENT RESERPINE
Common Name English
SERPASIL-ESIDRIX COMPONENT RESERPINE
Common Name English
RESERPINE [IARC]
Common Name English
RESERPINE COMPONENT OF UNIPRES
Common Name English
RESERPINE COMPONENT OF NAQUIVAL
Common Name English
APOPLON
Brand Name English
RESERPINE [USP-RS]
Common Name English
RESERPINE COMPONENT OF H.R.-50
Common Name English
SERPASIL-APRESOLINE COMPONENT RESERPINE
Common Name English
HYDROPRES COMPONENT RESERPINE
Common Name English
SERPALAN
Brand Name English
HYDRO-RESERP COMPONENT RESERPINE
Common Name English
RESERPINUM [HPUS]
Common Name English
reserpine [INN]
Common Name English
SALUTENSIN COMPONENT RESERPINE
Common Name English
RESERPINE COMPONENT OF SER-AP-ES
Common Name English
RESERPINE COMPONENT OF HYDROSERPINE PLUS (R-H-H)
Common Name English
NSC-59272
Code English
DRALSERP COMPONENT RESERPINE
Common Name English
UNIPRES COMPONENT RESERPINE
Common Name English
METHYL 18.BETA.-HYDROXY-11,17.ALPHA.-DIMETHOXY-3.BETA.,20.ALPHA.-YOHIMBAN-16.BETA.-CARBOXYLATE 3,4,5-TRIMETHOXYBENZOATE (ESTER).
Common Name English
NAQUIVAL COMPONENT RESERPINE
Common Name English
Reserpine [WHO-DD]
Common Name English
METHYL (3.BETA.,16.BETA.,17.ALPHA.,18.BETA.,20.ALPHA.)-11,17-DIMETHOXY-18-((3,4,5-TRIMETHOXYBENZOYL)OXY)YOHIMBAN-16-CARBOXYLATE
Common Name English
SER-AP-ES COMPONENT RESERPINE
Common Name English
Classification Tree Code System Code
WHO-ATC C02LA71
Created by admin on Fri Dec 16 16:36:58 UTC 2022 , Edited by admin on Fri Dec 16 16:36:58 UTC 2022
NCI_THESAURUS C1744
Created by admin on Fri Dec 16 16:36:58 UTC 2022 , Edited by admin on Fri Dec 16 16:36:58 UTC 2022
WHO-ATC C02AA52
Created by admin on Fri Dec 16 16:36:58 UTC 2022 , Edited by admin on Fri Dec 16 16:36:58 UTC 2022
NDF-RT N0000175650
Created by admin on Fri Dec 16 16:36:58 UTC 2022 , Edited by admin on Fri Dec 16 16:36:58 UTC 2022
WHO-ATC C02LA01
Created by admin on Fri Dec 16 16:36:58 UTC 2022 , Edited by admin on Fri Dec 16 16:36:58 UTC 2022
NCI_THESAURUS C29747
Created by admin on Fri Dec 16 16:36:58 UTC 2022 , Edited by admin on Fri Dec 16 16:36:58 UTC 2022
WHO-ATC C02LA51
Created by admin on Fri Dec 16 16:36:58 UTC 2022 , Edited by admin on Fri Dec 16 16:36:58 UTC 2022
WHO-VATC QC02LA51
Created by admin on Fri Dec 16 16:36:58 UTC 2022 , Edited by admin on Fri Dec 16 16:36:58 UTC 2022
WHO-ATC C02AA02
Created by admin on Fri Dec 16 16:36:58 UTC 2022 , Edited by admin on Fri Dec 16 16:36:58 UTC 2022
NDF-RT N0000175640
Created by admin on Fri Dec 16 16:36:58 UTC 2022 , Edited by admin on Fri Dec 16 16:36:58 UTC 2022
EPA PESTICIDE CODE 123101
Created by admin on Fri Dec 16 16:36:58 UTC 2022 , Edited by admin on Fri Dec 16 16:36:58 UTC 2022
WHO-VATC QC02AA02
Created by admin on Fri Dec 16 16:36:58 UTC 2022 , Edited by admin on Fri Dec 16 16:36:58 UTC 2022
WHO-VATC QC02LA01
Created by admin on Fri Dec 16 16:36:58 UTC 2022 , Edited by admin on Fri Dec 16 16:36:58 UTC 2022
WHO-VATC QC02AA52
Created by admin on Fri Dec 16 16:36:58 UTC 2022 , Edited by admin on Fri Dec 16 16:36:58 UTC 2022
WHO-VATC QC02LA71
Created by admin on Fri Dec 16 16:36:58 UTC 2022 , Edited by admin on Fri Dec 16 16:36:58 UTC 2022
LIVERTOX NBK548348
Created by admin on Fri Dec 16 16:36:58 UTC 2022 , Edited by admin on Fri Dec 16 16:36:58 UTC 2022
IARC Reserpine
Code System Code Type Description
MERCK INDEX
M9535
Created by admin on Fri Dec 16 16:36:58 UTC 2022 , Edited by admin on Fri Dec 16 16:36:58 UTC 2022
PRIMARY Merck Index
INN
282
Created by admin on Fri Dec 16 16:36:58 UTC 2022 , Edited by admin on Fri Dec 16 16:36:58 UTC 2022
PRIMARY
DAILYMED
8B1QWR724A
Created by admin on Fri Dec 16 16:36:58 UTC 2022 , Edited by admin on Fri Dec 16 16:36:58 UTC 2022
PRIMARY
DRUG CENTRAL
2370
Created by admin on Fri Dec 16 16:36:58 UTC 2022 , Edited by admin on Fri Dec 16 16:36:58 UTC 2022
PRIMARY
DRUG BANK
DB00206
Created by admin on Fri Dec 16 16:36:58 UTC 2022 , Edited by admin on Fri Dec 16 16:36:58 UTC 2022
PRIMARY
PUBCHEM
5770
Created by admin on Fri Dec 16 16:36:58 UTC 2022 , Edited by admin on Fri Dec 16 16:36:58 UTC 2022
PRIMARY
NCI_THESAURUS
C803
Created by admin on Fri Dec 16 16:36:58 UTC 2022 , Edited by admin on Fri Dec 16 16:36:58 UTC 2022
PRIMARY
IUPHAR
4823
Created by admin on Fri Dec 16 16:36:58 UTC 2022 , Edited by admin on Fri Dec 16 16:36:58 UTC 2022
PRIMARY
CAS
50-55-5
Created by admin on Fri Dec 16 16:36:58 UTC 2022 , Edited by admin on Fri Dec 16 16:36:58 UTC 2022
PRIMARY
RS_ITEM_NUM
1601000
Created by admin on Fri Dec 16 16:36:58 UTC 2022 , Edited by admin on Fri Dec 16 16:36:58 UTC 2022
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
RESERPINE
Created by admin on Fri Dec 16 16:36:58 UTC 2022 , Edited by admin on Fri Dec 16 16:36:58 UTC 2022
PRIMARY Description: Small, white to pale beige crystals or a white to pale beige, crystalline powder; odourless. Solubility: Practically insoluble in water; soluble in 90 parts of acetone R; very slightly soluble in methanol R, ethanol (~750 g/l) TS, and ether R. Category: Neuroleptic; hypotensive. Storage: Reserpine should be kept in a well-closed container, protected from light.Additional information: Reserpine darkens slowly on exposure to light, but more rapidly in solution. Definition: Reserpine contains not less than 98.0% and not more than 102.0% of C33H40N2O9, calculated with reference to thedried substance.
FDA UNII
8B1QWR724A
Created by admin on Fri Dec 16 16:36:58 UTC 2022 , Edited by admin on Fri Dec 16 16:36:58 UTC 2022
PRIMARY
EPA CompTox
DTXSID7021237
Created by admin on Fri Dec 16 16:36:58 UTC 2022 , Edited by admin on Fri Dec 16 16:36:58 UTC 2022
PRIMARY
ECHA (EC/EINECS)
200-047-9
Created by admin on Fri Dec 16 16:36:58 UTC 2022 , Edited by admin on Fri Dec 16 16:36:58 UTC 2022
PRIMARY
EVMPD
SUB10286MIG
Created by admin on Fri Dec 16 16:36:58 UTC 2022 , Edited by admin on Fri Dec 16 16:36:58 UTC 2022
PRIMARY
HSDB
213
Created by admin on Fri Dec 16 16:36:58 UTC 2022 , Edited by admin on Fri Dec 16 16:36:58 UTC 2022
PRIMARY
NSC
237659
Created by admin on Fri Dec 16 16:36:58 UTC 2022 , Edited by admin on Fri Dec 16 16:36:58 UTC 2022
PRIMARY
ChEMBL
CHEMBL772
Created by admin on Fri Dec 16 16:36:58 UTC 2022 , Edited by admin on Fri Dec 16 16:36:58 UTC 2022
PRIMARY
CHEBI
28487
Created by admin on Fri Dec 16 16:36:58 UTC 2022 , Edited by admin on Fri Dec 16 16:36:58 UTC 2022
PRIMARY
RXCUI
9260
Created by admin on Fri Dec 16 16:36:58 UTC 2022 , Edited by admin on Fri Dec 16 16:36:58 UTC 2022
PRIMARY RxNorm
WIKIPEDIA
RESERPINE
Created by admin on Fri Dec 16 16:36:58 UTC 2022 , Edited by admin on Fri Dec 16 16:36:58 UTC 2022
PRIMARY
NSC
59272
Created by admin on Fri Dec 16 16:36:58 UTC 2022 , Edited by admin on Fri Dec 16 16:36:58 UTC 2022
PRIMARY
MESH
D012110
Created by admin on Fri Dec 16 16:36:58 UTC 2022 , Edited by admin on Fri Dec 16 16:36:58 UTC 2022
PRIMARY
LACTMED
Reserpine
Created by admin on Fri Dec 16 16:36:58 UTC 2022 , Edited by admin on Fri Dec 16 16:36:58 UTC 2022
PRIMARY